Shattuck Labs shares surge 14.29% intraday after HC Wainwright & Co. upgrades stock to buy with $6 price target.

Monday, Dec 1, 2025 9:46 am ET1min read
Shattuck Labs surged 14.29% intraday, driven by HC Wainwright & Co. upgrading its stock rating to Buy with a $6 target price effective December 1, 2025. The company specializes in developing therapies for inflammatory bowel disease and immune disorders, with its core project being the novel death receptor 3 antagonist SL-325 in the tumor necrosis factor receptor therapy area.

Comments



Add a public comment...
No comments

No comments yet